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MaBACKGROUND Natriuretic peptides (NP) have prognostic value in heart failure (HF), although the clinical importance
of changes in NP from baseline is unclear.
OBJECTIVES The authors assessed whether a reduction in N-terminal pro–B-type NP (NT-proBNP) was associated with
a decrease in HF hospitalization and cardiovascular mortality (primary endpoint) in patients with HF and reduced ejection
fraction, whether treatment with sacubitril/valsartan reduced NT-proBNP below specific partition values more than
enalapril, and whether the relationship between changes in NT-proBNP and changes in the primary endpoint were
dependent on assigned treatment.
METHODS In PARADIGM-HF (Prospective Comparison of ARNI [Angiotensin Receptor–Neprilysin Inhibitor] with ACEI
[Angiotensin-Converting–Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial),
baseline NT-proBNP was measured in 2,080 patients; 1,292 had baseline values >1,000 pg/ml and were reassessed at
1 and 8 months. We related change in NT-proBNP to outcomes.
RESULTS One month after randomization, 24% of the baseline NT-proBNP levels >1,000 pg/ml had fallen to #1,000
pg/ml. Risk of the primary endpoint was 59% lower in patients with a fall in NT-proBNP to #1,000 pg/ml than in those
without such a fall. In sacubitril/valsartan-treated patients, median NT-proBNP was significantly lower 1 month after
randomization than in enalapril-treated patients, and it fell to #1,000 pg/ml in 31% versus 17% of patients treated with
sacubitril/valsartan and enalapril, respectively. There was no significant interaction between treatment and the rela-
tionship between change in NT-proBNP and the subsequent risk of the primary endpoint.
CONCLUSIONS Patients who attained a significant reduction in NT-proBNP had a lower subsequent rate of
cardiovascular death or HF hospitalization independent of the treatment group. Treatment with sacubitril/valsartan
was nearly twice as likely as enalapril to reduce NT-proBNP to values #1,000 pg/ml. (Prospective Comparison of ARNI
[Angiotensin Receptor–Neprilysin Inhibitor] with ACEI [Angiotensin-Converting–Enzyme Inhibitor] to Determine Impact on
Global Mortality and Morbidity in Heart Failure Trial) [PARADIGM-HF]; NCT01035255.) (J AmColl Cardiol 2016;68:2425–36)
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ABBR EV I A T I ON S
AND ACRONYMS
ACE = angiotensin-converting
enzyme
ARB = angiotensin receptor
blocker
BNP = B-type natriuretic
peptide
CHF = congestive heart failure
CI = confidence interval
HF = heart failure
HFrEF = heart failure with
reduced ejection fraction
HR = hazard ratio
IQR = interquartile range
NP = natriuretic peptide
NT-proBNP = N-terminal pro–
B-type natriuretic peptide
PARADIGM-HF = Prospective
Comparison of ARNI With ACEI
to Determine Impact on Global
Mortality and Morbidity in
Heart Failure
Zile et al. J A C C V O L . 6 8 , N O . 2 2 , 2 0 1 6
NT-proBNP in HFrEF D E C E M B E R 6 , 2 0 1 6 : 2 4 2 5 – 3 6
2426N atriuretic peptides (NPs), specif-ically B-type natriuretic peptide(BNP) and N-terminal pro–B-type
natriuretic peptide (NT-proBNP), have diag-
nostic and prognostic value in patients with
heart failure (HF) (1–6). Decreases in NP dur-
ing follow-up are associated with reduced
morbidity and mortality outcomes, whereas
increasing NP portends poor patient out-
comes (5–22). Clinical trials assessing
whether changes in NP from baseline could
be useful in evaluating treatment success
have yielded mixed results (23–31) and were
limited by small size, low event rates, effec-
tiveness of treatment strategies, frequency
of NP measurement, length of follow-up,
and NP partition values (32,33).SEE PAGE 2437Although the PARADIGM-HF (Prospective
Comparison of ARNI With ACEI to Determine
Impact on Global Mortality and Morbidity inHeart Failure) trial was not designed to address the
prognostic value of changes in NPs, the large sample
size, significant event rate, effectiveness of treat-
ment strategy, frequency of NP measurements, and
length of follow-up of PARADIGM-HF provide an
opportunity to address issues that limited earlier
reports (34,35). We analyzed data from PARADIGM-
HF to determine: 1) whether and to what degree a1 Change in NT-proBNP From Baseline (V2/V2a) to 1 Month A
n NT-proBNP
Month
All Patients
(N ¼ 1,942)
Sacubitril/Valsart
(n ¼ 971)
atients with NT-proBNP (of any value) at baseline
duction 1,262 (65.0) 729 (75.1)
tion >10% 1,106 (57.0) 667 (68.7)
tion >20% 910 (46.9) 562 (57.9)
tion >30% 709 (36.5) 461 (47.5)
tion >40% 523 (26.9) 358 (36.9)
tion >50% 357 (18.4) 256 (26.4)
e #10% 293 (15.1) 114 (11.7)
se 10%–50% 315 (16.2) 120 (12.4)
se >50% 228 (11.7) 70 (7.2)
All Patients
(N ¼ 1,207)
Sacubitril/Valsart
(n ¼ 612)
atients with NT-proBNP >1,000 mg/dl at baseline
BNP #1,000 pg/ml 288 (23.9) 187 (30.6)
BNP #750 pg/ml 154 (12.8) 108 (17.6)
BNP #500 pg/ml 67 (5.6) 52 (8.5)
n (%).
NP ¼ N-terminal pro–B-type natriuretic peptide.change in NT-proBNP was associated with a change
in morbidity and mortality rates in patients with HF
with reduced ejection fraction (HFrEF); 2) whether
treatment of HFrEF patients with sacubitril/valsar-
tan lowered NT-proBNP below specific partition
values more often than enalapril; and 3) whether the
relationship between change in NT-proBNP and
change in morbidity and mortality event rates was
influenced by treatment.
METHODS
STUDY PATIENTS. The design and primary results of
PARADIGM-HF were described previously (12). The
institutional review boards of 1,043 participating in-
stitutions (in 47 countries) approved the protocol,
and all patients gave written informed consent. Pa-
tients had New York Heart Association functional
class II to IV symptoms, an ejection fraction of #35%,
and a BNP $150 pg/ml (or NT-proBNP $600 pg/ml), or
if they had been hospitalized for HF within the pre-
vious 12 months, a BNP $100 pg/ml (or an NT-
proBNP $400 pg/ml) (12). Patients taking any dose
of angiotensin-converting enzyme (ACE) inhibitor or
angiotensin receptor blocker (ARB) and able to
tolerate the equivalent of enalapril 10 mg daily for $4
weeks before screening, along with stable doses of a
b-blocker (unless contraindicated or not tolerated)
and a mineralocorticoid antagonist (if indicated),
were included. Patients were excluded for a history of
intolerance to ACE inhibitors or ARBs (12).fter Randomization (V7)
an Enalapril
(n ¼ 971)
Between Treatment
Odds Ratio 95% CI p Value
533 (54.9) 2.48 2.04–3.00 <0.001
439 (45.2) 2.66 2.21–3.20 <0.001
348 (35.8) 2.46 2.05–2.95 <0.001
248 (25.5) 2.64 2.18–3.19 <0.001
165 (17.0) 2.85 2.31–3.53 <0.001
101 (10.4) 3.08 2.40–3.96 <0.001
179 (18.4) 0.59 0.46–0.76 <0.001
195 (20.1) 0.56 0.44–0.72 <0.001
158 (16.3) 0.40 0.30–0.54 <0.001
an Enalapril
(n ¼ 595)
101 (17.0) 2.15 1.63–2.83 <0.001
46 (7.7) 2.55 1.77–3.68 <0.001
15 (2.5) 3.58 1.99–6.44 <0.001
FIGURE 1 Effects on Risk of Primary Endpoint if NT-proBNP Achieved or Did Not Achieve a Value of <1,000 pg/ml 1 Month
After Randomization
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Risk of primary endpoint after 1 month of randomization in patients with a baseline N-terminal pro–B-type natriuretic peptide (NT-proBNP) (V2/V2a) >1,000
pg/ml who had a reduction in NT-proBNP at 1 month after randomization (V7) versus those patients who did not achieve a reduction in NT-proBNP at
1 month after randomization. The risk at 3 yrs of follow-up was z50% less in those who achieved a NT-proBNP #1,000 pg/ml than in those who did not.
TABLE 2 Effect on Primary Event Rate of a Change in NT-proBNP From Baseline (V2/V2a) to 1 Month After Randomization (V7)
Change in NT-proBNP at 1 Month
n HR 95% CI p Value n HR 95% CI p Value n HR 95% CI p Value
All Patients (N ¼ 1,942) Sacubitril/Valsartan (n ¼ 971) Enalapril (n ¼ 971)
Among patients with NT-proBNP
(of any value) at baseline
Any reduction 1,262 0.76 0.63–0.93 0.007 729 0.71 0.52–0.96 0.028 533 0.84 0.65–1.10 0.205
Reduction >10% 1,106 0.78 0.64–0.94 0.010 667 0.79 0.59–1.07 0.129 439 0.80 0.61–1.05 0.108
Reduction >20% 910 0.77 0.64–0.94 0.011 562 0.79 0.59–1.05 0.104 348 0.81 0.61–1.07 0.137
Reduction >30% 709 0.78 0.63–0.96 0.017 461 0.85 0.64–1.13 0.258 248 0.75 0.54–1.03 0.078
Reduction >40% 523 0.79 0.62–0.99 0.040 358 0.84 0.62–1.13 0.248 165 0.78 0.53–1.14 0.202
Reduction >50% 357 0.75 0.57–0.99 0.041 256 0.79 0.56–1.11 0.169 101 0.77 0.48–1.25 0.295
Among patients with NT-proBNP
(of any value) at baseline
(adjusted for baseline NT-proBNP)
Any reduction 1,262 0.62 0.50–0.75 <0.001 729 0.56 0.41–0.77 <0.001 533 0.69 0.52–0.90 0.007
Reduction >10% 1,106 0.63 0.52–0.77 <0.001 667 0.63 0.47–0.85 0.003 439 0.66 0.50–0.87 0.003
Reduction >20% 910 0.63 0.51–0.77 <0.001 562 0.62 0.46–0.83 0.001 348 0.66 0.49–0.88 0.005
Reduction >30% 709 0.63 0.51–0.78 <0.001 461 0.68 0.51–0.92 0.011 248 0.60 0.43–0.84 0.003
Reduction >40% 523 0.61 0.48–0.77 <0.001 358 0.65 0.47–0.88 0.006 165 0.58 0.39–0.86 0.007
Reduction >50% 357 0.57 0.43–0.76 <0.001 256 0.58 0.41–0.82 0.002 101 0.59 0.36–0.97 0.036
All Patients (N ¼ 1,207) Sacubitril/Valsartan (n ¼ 612) Enalapril (n ¼ 595)
Among patients with NT-proBNP
>1,000 pg/ml at baseline
NT-proBNP #1,000 pg/ml 288 0.41 0.29–0.58 <0.001 187 0.44 0.29–0.68 <0.001 101 0.38 0.21–0.67 0.001
NT-proBNP #750 pg/ml 154 0.46 0.29–0.71 0.001 108 0.49 0.29–0.83 0.009 46 0.43 0.19–0.97 0.041
NT-proBNP #500 pg/ml 67 0.64 0.36–1.14 0.129 52 0.58 0.28–1.18 0.134 15 0.92 0.34–2.49 0.875
CI ¼ confidence interval; HR ¼ hazard ratio; NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide.
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FIGURE 2 Effects on Risk of Primary Endpoint if N-Terminal Pro–B-Type Natriuretic Peptide Changed From Baseline to 1 Month After Randomization:
High-High, High-Low, Low-High Analysis
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Categorical analysis. Patients were divided into 4 categorical groups described in the Methods. (A) The lowest primary event rate occurred in the Low-Low group; the
highest primary event rate occurred in the High-High group; the High-Low and Low-High groups had intermediate primary event rates. (B) Hazard ratio (HR) and 95%
confidence intervals for each category, with High-High serving as a reference.
TABLE 3 Change in NT-proBNP From Baseline (V2/V2a) to 1 Month After Randomization
(V7): Categorical Analysis
Change in NT-proBNP
at 1 Month
All Patients
(N ¼ 1,942)
Sacubitril/Valsartan
(n ¼ 971)
Enalapril
(n ¼ 971)
Between Treatments
OR† 95% CI p Value
Among patients with
NT-proBNP
>1,000 pg/ml at
baseline
(N ¼ 1,206) (n ¼ 612) (n ¼ 594)
High-High* 918 (76.1) 425 (69.4) 493 (83.0)
High-Low 288 (23.9) 187 (30.6) 101 (17.0) 2.15 1.63–2.83 <0.001
Among patients with
NT-proBNP #
1,000 pg/ml
at baseline
(N ¼ 736) (n ¼ 359) (n ¼ 377)
Low-High 124 (16.8) 38 (10.6) 86 (22.8)
Low-Low 612 (83.2) 321 (89.4) 291 (77.2) 2.5 1.62–3.88 <0.001
Values are n (%). *High ¼ NT-proBNP > 1,000 pg/ml; Low ¼ NT-proBNP #1,000 pg/ml. †OR for patients in the
High-High group having a reduction of NT-proBNP that converted them to the High-Low group was twice as
likely in those treated with sacubitril/valsartan versus those treated with enalapril (OR: 2.15); the OR of patients
in the Low-Low group maintaining this low value of NT-proBNP and remaining in the Low-Low group was twice
as likely in those treated with sacubitril/valsartan versus those treated with enalapril (OR: 2.50).
NT-proBNP ¼ N-terminal pro–B-type natriuretic peptide; OR ¼ odds ratio.
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2428STUDY PROCEDURES. At trial entry, all ACE in-
hibitors or ARBs were stopped, but other HF treat-
ments were continued. Patients then received
enalapril 10 mg twice daily for 2 weeks (single blind)
followed by sacubitril/valsartan (single blind) for 4 to
6 weeks, initially at 49 mg/51 mg (100 mg of LCZ696)
twice daily and then 97 mg/103 mg (200 mg of
LCZ696) twice daily. Patients tolerating both drugs at
target doses were randomized in a 1:1 ratio to double-
blind treatment with either enalapril 10 mg twice
daily or sacubitril/valsartan 97 mg/103 mg twice daily.
The enalapril dose was selected on the basis of its
effect in reducing mortality in the Studies of Left
Ventricular Dysfunction Treatment Trial (36); higher
doses have not been more effective or well tolerated
long-term (36–38). After randomization, patients
were maintained on the highest tolerated doses of the
study medication. Worsening HF was treated by
adjusting the doses of any concomitant drug and us-
ing any interventions that were clinically indicated.
Mean follow-up was 2.4 years.
FIGURE 3 Association Between Change in NT-proBNP and Primary Endpoint:
Continuous Analysis
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Landmark analysis of primary events starting at 1 month after randomization. The change
from baseline to month 1 after randomization was a highly significant predictor of sub-
sequent events. Changes from baseline data are presented as Log2(1 month NT-proBNP
after randomization / baseline NT-proBNP). A 0 value represents no change from base-
line, þ1 represents a doubling of NT-proBNP at 1 month compared with baseline, and -1
represents a halving of NT-proBNP at 1 month compared with baseline. Increases in NT-
proBNP were associated with increased risk (hazard ratio [HR] per doubling of NT-proBNP:
1.24; 95% confidence interval [CI]: 1.11 to 1.38; p < 0.001), whereas decreases in NT-
proBNP were associated with lower risk (HR per halving of NT-proBNP: 0.81; 95% CI: 0.72
to 0.90). These results were not adjusted for baseline values of NT-proBNP. When
adjusted for baseline NT-pro-BNP, HR was 1.46 per doubling (95% CI: 1.30 to 1.64;
p < 0.001) and 0.68 per halving (95% CI: 0.61 to 0.77; p < 0.001). Solid horizontal line
indicates an HR of 1.00. Solid oblique line (± dashed lines) indicates the calculated HR for
patient population studied ( 95% CI).
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2429NT-proBNP ASSAY. The principal analysis was change
in plasma NT-proBNP. NT-proBNP was measured at 5
time points: baseline before run-in (V2/V2a, n ¼ 2,080
[1,051 subsequently treated with sacubitril/valsartan,
1,029 with enalapril]), after enalapril run-in (V3,
n ¼ 875 [440 treated with sacubitril/valsartan, 435
with enalapril]), at randomization (V5, n ¼ 2,015
[1,018 treated with sacubitril/valsartan, 997 with
enalapril]), at 1 month (V7, n ¼ 1,942 [971 treated
with sacubitril/valsartan, 971 with enalapril]), and at
8 months (V10, n ¼ 1,759 [885 treated with sacubi-
tril/valsartan, 874 with enalapril]) after randomiza-
tion (Online Figure 1). Plasma NT-proBNP was
measured with the Roche Elecsys proBNP assay
(Roche Diagnostics GmbH, Mannheim, Germany).
The coefficient of variation for NT-proBNP deter-
mined with the Roche Elecsys proBNP assay (Roche
Diagnostics) was <2.5% at all levels tested between
47 pg/ml and 34,160 pg/ml. All available data at each
time point were used to examine the change in NT-
proBNP over time and the effect of treatment on
NT-proBNP. All analyses were performed only in
those patients who had both a baseline and a post-
randomization measurement at the specified time
point.
STATISTICAL ANALYSIS. Only the primary study
endpoint (the first occurrence of cardiovascular death
or HF hospitalization) was examined. To assess the
relationship between change in NT-proBNP from
baseline and subsequent risk of a primary endpoint,
we performed several landmark analyses, starting
with the 1-month post-randomization visit. First,
among patients with elevated NT-proBNP values at
baseline (>1,000 pg/ml), the hazard ratios (HRs)
associated with attaining or not attaining post-
baseline NT-proBNP values below specific thresh-
olds were estimated. An initial threshold of
#1,000 pg/ml was chosen on the basis of previous and
ongoing studies (34–44), but analyses were also
performed using thresholds of #750 pg/ml and
#500 pg/ml. For each of these analyses, only those
patients with a baseline NT-proBNP >1,000 pg/ml
were examined. However, all patients with paired
samples at baseline and 1 month were used for the
landmark analysis of threshold changes of 10%, 20%,
30%, 40%, and 50% reduction from baseline.
Next, based on NT-proBNP values at baseline and
at 1 month, patients were grouped into 4 categories:
NT-proBNP #1,000 pg/ml at both baseline and 1
month (Low-Low group); NT-proBNP >1,000 pg/ml)
at baseline and 1 month (High-High group); NT-
proBNP >1,000 pg/ml at baseline and #1,000 pg/ml
at 1 month (High-Low group); and NT-proBNP#1,000 pg/ml at baseline and >1,000 pg/ml at 1
month (Low-High group). Kaplan-Meier curves and
Cox proportional hazards models were used to char-
acterize risk of subsequent events in each group. In
addition, among all patients, the HRs associated with
attaining or not attaining specific relative reductions
in NT-proBNP were estimated, with and without
adjustment for the log-transformed baseline
NT-proBNP value. We created mutually exclusive
categories of relative NT-proBNP reduction and
reported event rates for each group, in all patients,
and then for each treatment group. Between-group
comparisons were made with respect to randomized
treatment and interactions between treatment and
changes in NT-proBNP.
The association between relative changes in NT-
proBNP from baseline (using log2–transformed
values) and differences in risk of subsequent events
was assessed with Cox proportional hazards models,
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2430with and without adjustment for baseline NT-
proBNP. The impact of randomized therapy on post-
baseline NT-proBNP values was compared using the
median (interquartile range [IQR]) for each treatment
arm at each time point, with differences assessed for
significance by Wilcoxon rank sum test. Proportions
of patients experiencing the specific reductions
described previously were compared with odds ratios
describing the relative increase or decrease in fre-
quency associated with study medication. Whether
baseline NT-proBNP (based on a quartile analysis)
modified the treatment effect of sacubitril/valsartan
compared with enalapril on the primary event rate
was assessed by 2 analyses. We tested for interaction
between randomized therapy and quartiles of base-
line NT-proBNP values (V2/V2a, n ¼ 2,080) and
estimated subgroup-specific treatment effects. ToFIGURE 4 NT-proBNP Values in Patients Treated With Sacubitril/Va
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Enalapril
both arms
3-6 wk
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Valsartan
both arms
V2/V2a
1303 (781;2371)
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1029
Sacubitril/Valsartan
n
Enalapril
n
NT-proBNP (pg/mL) Median (Q1;Q3)
V3
1251 (653;2208)
440
1276 (698;2186)
435
V3
Median N-terminal pro–B-type natriuretic peptide (NT-proBNP) values in
versus enalapril-treated patients (orange squares, orange dashed line) a
(interquartile range: Q1;Q3) in patients with values available at each tim
significantly lower in the sacubitril/valsartan-treated patients than in th
*p < 0.05. V2/V2a ¼ baseline before run-in; V3 ¼ after enalapril run-in
and V10 ¼ 8 months after randomization.increase power to detect meaningful differences in
treatment effect, we repeated this analysis using
NT-proBNP values obtained at screening (average 13
days before baseline, n ¼ 8,348) and analyzed at local
study sites (not at a central core laboratory).
p Values <0.05 were considered statistically signifi-
cant. No adjustments of the type I error were made for
multiple testing. All analyses were conducted with
STATA version 14.1 (Stata Corp., College Station,
Texas).
RESULTS
CHANGE IN NT-proBNP AND CHANGE IN PRIMARY
EVENT RATE. Overall, 2,080 patients had NT-proBNP
measured at baseline, of whom 1,292 patients (62%)
had values >1,000 pg/ml. Baseline characteristicslsartan Versus Enalapril at Each Study Time Point
domization
Post Randomization
1 Mo 8 Mo
Sacubitril/Valsartan
Enalapril
*p<0.0001 vs Enalapril
V7
938 (511;1595)
971
1203 (711;2061)
971
V7
V5
917 (526;1653)
1018
882 (517;1692)
997
V5
V10
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885
1102 (610;2073)
874
V10
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Percent of patients with N-terminal pro–B-type natriuretic peptide (NT-proBNP)
>1,000 pg/ml at baseline achieving lower numeric value 1 month or 8 months after
randomization. Data are divided into patients treated with sacubitril/valsartan (orange
bars) versus patients treated with enalapril (blue bars). Sacubitril/valsartan treatment
resulted in a significantly larger number of patients achieving a NT-proBNP less than
each partition value examined compared with enalapril treatment. *p < 0.05, sacubitril/
valsartan versus enalapril.
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2431for patients with baseline NT-proBNP >1,000
versus #1,000 pg/ml are presented in Online Table 1.
One month after randomization, 24% of the baseline
elevated NT-proBNP levels had fallen to #1,000 pg/ml
(Table 1); in those patients, risk of a subsequent pri-
mary endpoint was 59% lower (HR: 0.41; 95% confi-
dence interval [CI]: 0.29 to 0.58; p < 0.0001) than in
patients without a fall in NT-proBNP to #1,000 pg/ml
at 1 month (Figure 1, Table 2). Similar lower rates of
the primary event rate were seen in patients with NT-
proBNP >1,000 pg/ml at baseline when the 1-month
partition value was set to a reduction in NT-proBNP
of #750 and #500 pg/ml (Table 2). In addition, the
risk of a primary event was significantly lower when
the decrease in NT-proBNP from baseline to 1 month
after randomization was measured as a percent
change; this analysis included all patients with a
measured NT-proBNP at baseline and 1 month
(Table 1).
Using a categorical analysis (Figure 2, Table 3), the
lowest primary event rate occurred in patients in the
Low-Low group, and the highest primary event rate
was seen in patients in the High-High group. Patients
in the High-Low group and Low-High group had in-
termediate rates of the primary event. Baseline
characteristics for patients in each group are pre-
sented in Online Table 2.
Using a continuous analysis (Figure 3, Online
Table 3), the change from baseline to month 1 was
a highly significant predictor of subsequent events;
the primary event rate increased as the value of NT-
proBNP increased at 1 month, and the primary event
rate decreased as the value of NT-proBNP decreased
at 1 month. After adjustment for baseline NT-
proBNP, the HR per doubling of NT-proBNP at 1
month was 1.46 (95% CI: 1.30 to 1.64), whereas the
HR per halving of NT-proBNP at 1 month was 0.68
(95% CI: 0.61 to 0.77).
TREATMENT WITH SACUBITRIL/VALSARTAN VERSUS
ENALAPRIL. Median NT-proBNP at baseline was 1,269
(IQR: 762 to 2,184) pg/ml for enalapril-treated pa-
tients and 1,303 (IQR: 781 to 2,371) pg/ml for sacubi-
tril/valsartan treated patients (Figure 4). The median
NT-proBNP did not change significantly during the
enalapril run-in but decreased significantly during
the sacubitril/valsartan run-in. One month after
randomization, NT-proBNP was significantly lower
in the sacubitril/valsartan-treated patients (938
[IQR: 511 to 1,595] pg/ml) compared with enalapril-
treated patients (1,203 [IQR: 711 to 2,061] pg/ml;
p < 0.001) for the difference between groups. At this
time, NT-proBNP fell to #1,000 pg/ml in 31% of
sacubitril/valsartan-treated patients versus 17% ofenalapril-treated patients (odds ratio: 2.15; 95% CI:
1.63 to 2.83; p < 0.0001) (Table 1, Figure 5). Among
patients with NT-proBNP reduction to #1,000 pg/ml
at 1 month and available NT-proBNP data at 8
months, NT-proBNP remained #1,000 pg/ml in 74%
of those treated with sacubitril/valsartan versus 59%
of those treated with enalapril treated (p ¼ 0.011).
Similar results were seen when the partition
value was set at a reduction in NT-proBNP #750
and #500 pg/ml (Table 1, Figure 5); a larger proportion
of patients treated with sacubitril/valsartan achieved
these reductions than enalapril-treated patients. A
similar differential treatment effect on the changes in
NT-proBNP, measured as a percent reduction from
baseline to 1 month after randomization (Table 1) and
using the categorical analysis (Table 3), was seen with
sacubitril/valsartan versus enalapril. In each analysis,
a reduction in NT-proBNP or maintenance of a low
NT-proBNP occurred more frequently in patients
treated with sacubitril/valsartan than enalapril.
EFFECT OF BASELINE AND CHANGE IN NT-proBNP
LEVELS ON TREATMENT EFFECT OF SACUBITRIL/
VALSARTAN VERSUS ENALAPRIL AND THE PRIMARY
EVENT RATE. Although baseline NT-proBNP was pre-
dictive of subsequent events in both treatment arms,
FIGURE 6 Effect o
NT-proBNP and Prim
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2432baseline NT-proBNP did not modify the treatment
effect of sacubitril/valsartan versus enalapril (p for
interaction ¼ 0.35) (Figure 6). In each quartile of
baseline NT-proBNP, treatment with sacubitril/val-
sartan decreased the primary event rate compared
with treatment with valsartan (Figure 6). This result
was consistent using both the baseline (V2/V2a, pre-
run in patient group n ¼ 2,018) and screening (pa-
tient group n ¼ 8,348) NT-proBNP data.
There was no significant interaction between
treatment and the relationship between change in
NT-proBNP from baseline and the subsequent risk of
the primary endpoint (p ¼ 0.67 for interaction). In
patients treated with sacubitril/valsartan, risk of a
subsequent primary endpoint was 56% lower (HR:
0.44; 95% CI: 0.29 to 0.68; p < 0.001) in patients with
a fall in NT-proBNP to #1,000 pg/ml at 1 month than
in patients without such a fall. In patients treated
with enalapril, the risk of a subsequent primary
endpoint was 62% lower (HR: 0.38; 95% CI: 0.21 to
0.66; p ¼ 0.001) in patients with a fall in NT-proBNP
to #1,000 pg/ml at 1 month than in patients without
such a fall (Table 2, Online Figure 2). Similar results
were obtained when the partition value was set at a
reduction in NT-proBNP #750 pg/ml and #500 pg/ml
and when a percent reduction in NT-proBNP from
baseline to 1 month after randomization wasf Randomized Therapy on Relationship Between Baseline
ary Event Rate
Hazard Ratio
Favors
Enalapril
Favors
Sacubitril / Valsartan
Median (Min,Max), N
1 20.90.80.70.60.50.4
Interaction p = 0.35
08 (10;84178), 8348
: 639 (10;884), 2090
197 (885;1608), 2085
0 (1609;3224), 2088
1 (3225;84178), 2085
0.3
nt impact of randomized therapy on the relationship between baseline
e natriuretic peptide (NT-proBNP) and the primary event rate. In each
T-proBNP, treatment with sacubitril/valsartan decreased the primary
with treatment with valsartan.examined (Table 2, Online Figure 3). There were no
significant interactions between treatment and the
relationship between change in NT-proBNP and the
subsequent risk of the primary endpoint for any of
these analyses (all p > 0.40) (Table 3, Online
Figure 4).
The differences in effects of enalapril versus
sacubitril/valsartan on the relationship between
change in NT-proBNP and a change in the primary
event rate were examined by use of a continuous
analysis, unadjusted and adjusted for baseline NT-
proBNP values. NT-proBNP changes from baseline to
month 1 were a highly significant predictor of subse-
quent primary events for patients in both treatment
groups; adjusted for baseline NT-proBNP, the HR per
doubling for enalapril patients was 1.38 (95% CI: 1.16
to 1.63; p < 0.001) and the HR per doubling for pa-
tients assigned to sacubitril/valsartan was 1.54 (95%
CI: 1.30 to 1.82; p < 0.001; p for interaction ¼ 0.54)
(Online Figure 5).
DISCUSSION
In this study, a change in plasma NT-proBNP was
associated with a change in cardiovascular mortality
and HF hospitalization rate in patients with HFrEF.
Whether NT-proBNP fell to less than a specific
numeric value, decreased by a specific percentage
from baseline, or changed from a higher to a lower
value, these reductions were associated with a
significantly lower rate of morbidity and mortality.
Sacubitril/valsartan was nearly twice (z1.8 times) as
likely to cause a meaningful reduction in NT-proBNP
as enalapril. Furthermore, the relationship between
changes in NT-proBNP and changes in subsequent
risk of a primary endpoint event was independent of
treatment group assignment.
Sacubitril/valsartan reduces degradation of several
endogenous compensatory vasoactive peptides,
including BNP (35), by inhibiting neprilysin (Central
Illustration). These actions can produce both hemo-
dynamic and biological benefits that reduce the
stimulus for NP synthesis, leading to the observed
decrease in NT-proBNP, which is not a substrate for
neprilysin and thus remains a good marker of the
severity of HF even in the setting of neprilysin inhi-
bition. Therefore, treatment with sacubitril/valsartan
would be expected to both increase BNP and decrease
NT-proBNP. Hemodynamic benefits produced by
other treatments for HF could also lead to a reduction
in NT-proBNP. ACE inhibitors and ARBs, by causing
vasodilation, afterload reduction, reverse remodel-
ing, and perhaps other effects, and cardiac resynch-
ronization therapy, by causing reverse remodeling,
CENTRAL ILLUSTRATION NT-proBNP in Patients With Heart Failure: Prognostic Implications of Changes
Zile, M.R. et al. J Am Coll Cardiol. 2016;68(22):2425–36.
Sacubitril/Valsartan is a first-in-class neprilysin, angiotensin receptor inhibitor that promotes vasodilation and reduces vasoconstriction (A). Effects of sacubitril/val-
sartan could be due to direct biochemical inhibition of neprilysin and the resultant biological effect on the determinants of natriuretic synthesis. By inhibiting neprilysin,
sacubitril/valsartan reduces degradation of B-type natriuretic peptide (BNP), resulting in an increase in BNP (C) and other vasoactive peptides. This might decrease both
preload and afterload through diuretic and cell signaling effects. Increases in BNP and other vasoactive peptides could reduce the stimulus for natriuretic peptide
synthesis by acting on the determinants of its synthesis; this conclusion is supported by the observed decrease in NT-proBNP (B). Treatment with sacubitril/valsartan
would be expected to both increase BNP and decrease NT-proBNP.
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2433also reduce NP levels, and changes in NP associated
with these therapies have been related to changes in
clinical outcomes.
In this analysis, changes in NT-proBNP had prog-
nostic significance, but the relationship between
change in NP and clinical outcomes has not been
consistent in other studies. In 1 meta-analysis of 21
trials using study-level data (5), change in BNP and
NT-proBNP was not correlated with drug- or device-
induced change in mortality. However, anothermeta-analysis that used individual patient data and
focused on hospitalization for HF as the primary
outcome (6) concluded that changes in BNP and NT-
proBNP were significantly associated with the
treatment-related changes in outcome.
Our analysis has a number of novel features. No
previous study examined the number and variety of
specific changes in NT-proBNP partition values and
related these changes to morbid and mortal out-
comes. We demonstrated the predictive value of
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: Patients with heart failure
and reduced left ventricular ejection fraction treated
with sacubitril plus valsartan are nearly twice as
likely to exhibit reductions in NT-proBNP values
to #1,000 pg/ml as those treated with enalapril,
and this is associated with a lower subsequent rate
of heart failure hospitalization or cardiovascular
death.
TRANSLATIONAL OUTLOOK: Further studies are
needed to elucidate the pathophysiological
mechanisms linking biomarkers to clinical outcomes
in patients with heart failure and to compare out-
comes achieved with biomarker-guided therapy with
those based on conventional clinical parameters
alone.
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change, categorical change, and continuous change
from baseline. The lack of interaction between NT-
proBNP reduction and treatment group with respect
to outcomes suggests that the prognostic value of a
change in NT-proBNP is similar in patients taking
sacubitril/valsartan and enalapril. However, the cur-
rent data should not be interpreted as having utility
in choosing which patients should receive continued
long-term treatment with sacubitril/valsartan versus
enalapril or when and if treatment should be termi-
nated. At all values of baseline NT-proBNP, sacubitril/
valsartan reduced the primary event rate compared
with enalapril. A sustained reduction in NT-proBNP
was significantly more likely with sacubitril/valsar-
tan than with enalapril.
One ongoing prospective study, GUIDE-IT (Guiding
Evidence Based Therapy Using Biomarker Intensified
Treatment in Heart Failure; NCT01685840) is
designed to evaluate the efficacy of a biomarker-
guided HF treatment strategy compared with opti-
mized medical therapy alone in a cohort of high-risk
patients with HFrEF (44). However, GUIDE-IT will
use a single NP partition value; the effects on out-
comes will be examined in patients with a baseline
>1,000 pg/ml who will be treated to target the
decrease in NT-proBNP to #1,000 pg/ml.
STUDY LIMITATIONS. The accuracy of the predictive
value of a change in any biomarker is in part depen-
dent on at least 2 factors that influence variability in
that biomarker. These include analytic variability
(imprecision of the test) and biological variability
(expected variability within the subject over time).
Although data evaluating the percent change in NT-
proBNP required to reflect a real change are limited,
1 study of 43 patients with congestive HF (CHF) (45)
and another of 23 CHF patients (46) estimated the
reference change value could range from 50% to 80%.
In the current study, the change from baseline data in
particular should therefore be interpreted in light ofthe influence of the biological variability known to be
present in CHF patients.
CONCLUSIONS
We demonstrated that a change in NT-proBNP, in-
dependent of the treatment group, was associated
with a change in the subsequent risk of cardiovas-
cular mortality and HF hospitalization and that
sacubitril/valsartan was twice as likely to cause a
prognostically meaningful reduction in NT-proBNP
as enalapril.
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